Abstracts used as both a profile and single score measure. LiSat-11 is a generic validated checklist for self-perceived satisfaction with life. A Finnish, age-matched male population cohort was used for comparison. RESULTS: A total of 194 patients provided data for analysis at baseline and outcome at 3 months. The changes observed (baseline to endpoint) were as follows: average usage of ED tablets per four weeks increased from 4.7 to 9.7, intercourse attempts from 6.4 to 10.6, and the success rate of intercourses from 79% to 92%. At baseline, the 15D score was higher for the study patients than for the comparator population (0.924 vs. 0.902). Nevertheless, significant improvement (baseline to endpoint) was reported on the 15D dimensions of mobility, depression, distress (all p < 0.01), and sexual activity (p < 0.001); and life in general (p < 0.05), leisure (p < 0.01), sexual life, family life, and partnership relation (all p < 0.001) domains of LiSat-11. CONCLUSIONS: When patients switched from other oral ED medication to tadalafil, improvement was seen in 3 of 15 dimensions of 15D and in 5 out of 11 domains of LiSat-11, including the closeness items: sexual life, partnership relation, and family life.
PIH19 ESTIMATING UTILITY IN ROTAVIRUS GASTROENTERITIS IN CHILDREN UNDER FIVE IN THE UK
Martin A 1 , Cotrell S 2 1 GlaxoSmithKline UK Limited, Uxbridge, UK, 2 IMS Health, London, England OBJECTIVE: To estimate the health state utility of differing severities of gastro-enteritis associated with rotavirus infection in children under five. METHODS: Health state descriptions were developed based on the major symptoms of gastro-enteritis infection. Health states for children who could be treated at home and those requiring hospitalisation were presented to GPs (N = 25), and for hospitalised cases, health states for children with two levels of dehydration were presented to paediatricians (N = 25). Both GPs and paediatricians were asked to score these health states using the EQ-5D questionnaire for children in two age bands (< 18 months, 1.5-5 years). Scores were modified to take into account the limited capacity for mobility and self-care among children in this age range. Utility estimates were calculated from these scores using standard methodology. RESULTS: From GP scores subjects requiring or not hospitalisation have a mean utility value (95% CI) of 0.425 (95 CI: 0.330; 0.520) and 0.781 (95 CI: 0.678; 0.884) in children <18 months, and 0.200 (95 CI: 0.049; 0.352) and 0.688 (95 CI: 0.553; 0.824) in children 1.5 yrs-5 yrs respectively. From paediatrician scores, mean utility values for hospitalised cases with 3-8% and ≥9% dehydration were 0.595 (95 CI: 0.528; 0.662) and 0.256 (95 CI: 0.157; 0.354) in children <18 months, and 0.634 (95 CI: 0.549; 0.718) and 0.077 (95 CI: −0.057; 0.210) in children 1.5 yrs-5 yrs respectively. In each case, confidence intervals between severe and less severe health states did not overlap. CONCLUSION: Gastroenteritis associated with rotavirus has a significant impact on the health related quality of life in children under five. This study provides useful estimates of health state utilities for economic evaluation of interventions to prevent rotavirus infection.
PIH20 CONJOINT-ANALYSIS QALYS FOR ACUTE CONDITIONS
Johnson FR, Hauber B, Ozdemir S RTI International, Research Triangle Park, NC, USA OBJECTIVE: Demonstrate using conjoint analysis to obtain generalized, nonlinear, time-tradeoff estimates of quality-adjusted life-years (QALYs) for clinically relevant durations and severities of acute, non-fatal conditions such as vasomotor symptoms.
METHODS:
A self-administered, web-enabled, graded-pairs conjoint-analysis survey elicited women's preferences for the treatment of vasomotor symptoms. The included treatment attributes are frequency and severity of vasomotor symptoms (daytime hot flashes and nighttime sweats) and duration of these symptoms. Participants also considered vasomotor-symptom, treatment-related side effects. Observed tradeoffs between symptom duration and symptom relief were used to calculate generalized conjoint time equivalents for specified health states without first calculating utilities anchored at 0 and 1. RESULTS: A total of 523 women with a mean age of 52 years completed the survey. For these women, improvement from severe (severe >6 hot flushes a day and >3 sweats a night) to moderate (moderate 3-6 hot flushes a day and 1-3 sweats a night) vasomotor symptoms over a 7-year treatment period is equivalent to 3.7 years of normal health, while improvement from moderate to mild (mild 1-2 hot flushes a day and no night sweats) symptoms is equivalent to 4.4 years of normal health. QALY benefits of symptom relief are larger for younger women (<= 2) than for older women (>52). For example, an improvement from moderate to mild is equivalent to 3.3 years of normal health for younger women, where it is to 6.8 years of normal health for older women. CONCLUSIONS: Conjoint analysis is a feasible method for estimating QALYs directly for acute health states. This approach avoids ad hoc approaches such as the chaining method. Its advantages over standard-gamble and time-tradeoff methods include avoiding clinically irrelevant tradeoffs involving death or life expectancy, avoiding restrictive assumptions such as linear time preferences, and eliciting preferences in the realistic context of both efficacy and side-effect risks.
PIH21 INFLUENCE OF CONCOMITANT DISEASES ON THE CLINICAL RESPONSE TO TREATMENT FOR ERECTILE DYSFUNCTION
Hospital Clínic, Barcelona, Spain, 2 Q.F Bayer, Barcelona, Spain, 3 Adelphi Targis, Barcelona, Spain Erectile dysfunction (ED) is defined as the persistent or recurring incapacity to achieve or maintain sufficient rigidity of the penis to be able to have satisfactory sexual intercourse. OBJECTIVE: To determine the clinical response to treatment (patient satisfaction, onset of action and reproducibility of the effect) in patients with ED, with or without other concomitant diseases. METHODS: A retrospective, epidemiological study was conducted in which we collected demographic data, medical and sexual history, concomitant medication, diagnostic and therapeutic procedures applied to ED and the clinical response to the prescribed treatment in male patients over 18 years of age who had visited their doctor in the 3 months prior to the start of the study. RESULTS: data was collected from 5281 patients. The most prevalent associated disorders were cardiovascular (28.6%), endocrine (23.7%) and genitourinary (15.4%). A total of 77.1% of the patients with concomitant disorders indicated they were satisfied with the erection obtained (sufficient for intercourse) (90.9% of the patients without other associated disorders; p < 0.0001). A totalof he patients with concomitant diseases referred they were satisfied with the onset of action of the treatment (91.1% without other associated disorders; p < 0.0001). 75.8% of the patients with concomitant diseases were confident to obtain and maintain a sufficient erection at each new attempt (90.0% without other associated disorders; p < 0.0001). Clinical response was better in patients with cardiovascular or endocrine conditions vs. genitourinary disorders (p < 0.03; p < 0.04). The mean prescribed dose was 15.9 mg (SD 5.2) of vardenafil, 18.6 mg (SD 6.9) of tadalafil and 60.6 mg (SD 23. Prior to use in an international study by NV Organon, the original 48-item menstrual Distress Questionnaire (MDQ), underwent linguistic validation in 26 languages. The original scale was developed in US English to assess the impact of common symptoms and feelings associated with the menstrual cycle. A rigorous methodology was required to ensure conceptual equivalence and cultural relevance across different languages. METHODS: The translation process was conducted by a specialist in each target country using the following standardized methodology: 1) two forward translations by professional translators who were native speakers of the target language and fluent in English; 2) comparison and reconciliation of the translations by the specialist in the target country and the translators; 3) back-translation by a native English speaker; 4) comparison of the original and back-translated versions; 5) review by a clinician; 6) comprehension test on 5 women; and 7) review for international comparability. RESULTS: The translation process revealed two major challenges. First, the formulation of some original items required the addition of a paraphrase or explanation in some languages. Second, the comprehension tests revealed that in countries where women are less used to completing questionnaires, the instructions asking the respondent to rate the same symptom/feeling for different times during a menstrual cycle were not always understood immediately. This required alternative wording in some translations. CONCLUSION: The 26 language versions of the MDQ were established according to a rigorous standardized translation methodology. The process aims to ensure conceptual equivalence across language versions to facilitate international comparison and pooling of data. The linguistic validation process illustrates the value of the integration of international feedback on concepts and wording during the translation of questionnaires.
PIH23 ERECTILE DYSFUNCTION IN SPAIN: CLINICAL RESPONSE TO TREATMENTS
Hospital Clínic, Barcelona, Spain, 2 Q.F Bayer, Barcelona, Spain, 3 Adelphi Targis, Barcelona, Spain Erectile dysfunction (ED) is defined as the persistent or recurring incapacity to achieve or maintain sufficient rigidity of the penis to be able to have satisfactory sexual intercourse. OBJECTIVES: To determine the clinical evaluation of the treatments prescribed in Spain for ED in terms of efficacy, patient satisfaction, onset of action, tolerability and reproducibility of the effect. METHODS: A retrospective epidemiological study was conducted in which we collected demographic data, medical and sexual history, concomitant medication, diagnostic and therapeutic procedures applied to ED and clinical response to the prescribed treatment, in male patients over 18 years of age who had visited a doctor in the 3 months prior to the start of the study. RESULTS: Data was collected from 5281 patients. 86.8% of those taking vardenafil obtained an erection that was sufficient for satisfactory intercourse vs. 59.1% with tadalafil and 45.2% with sildenafil (p < 0.0001). The time required to obtain the erection was considered satisfactory in 89.7% of the patients taking vardenafil vs. 65.2% with tadalafil and 44.8% with sildenafil (p < 0.0001). The tolerability of the prescribed treatment was satisfactory in 94.3% of the patients who took vardenafil vs. 77.8% with tadalafil and 74.0% with sildenafil (p < 0.0001). A total of 85.7% of the patients with ED who took vardenafil referred they were confident that they could obtain and maintain a sufficient erection in each new attempt vs. 57.1% with tadalafil and 44.6% with sildenafil (p < 0.0001). The mean prescribed dose of vardenafil was 15.9 mg (SD 5.2), 18.6 mg (SD 6.9) for tadalafil and 60.6 mg (SD 23.7) for sildenafil.CONCLUSIONS: Oral treatments for erectile dysfunction provide a good clinical response, observing a statistically higher response with vardenafil at a lower dose. To explore the feasibility of producing preferences in the Italian context. METHODS: We carried out a pilot experience to assess the preferences of Italian patients (pts) suffering from benign prostatic hyperplasia, using different techniques. Pts expressed their opinions on different scenarios (with/without drugs, TURP). Outcomes to be evaluated were: symptoms relief, risk of urinary retention, adverse events (AEs) etc. Pts were asked to: 1) rank the scenarios according to their preferences; 2) rate (0 to 100) any scenario: and 3) express their Willingness to Pay for each scenario. RESULTS: On a sample of 51 pts, the different methods showed similar results except for WTP, whose rationale was difficult to understand by pts. Among preference factors, pts ranked reducing the prostate volume and the risk of surgery at the top of the list; while reducing the risk of urinary retention and avoiding AEs were at the end. Data processing showed an inverse relation between preferences of minimizing AEs and efficacy. CONCLUSIONS: We found a lot of difficulties in measuring health preferences. The acceptance to take part into the study was poor. It is likely that the poor acceptance reflects the lack of interest by urologists and pts. Furthermore, the number of published papers on preferences by Italian authors is very scarce. In our opinion, likely explanations of this is that a) in Italy the National Health Service is free/almost free for everybody, and this leads to a difficult evaluation (in economic terms) of a health care intervention; b) scenarios to be evaluated are theoretical, not experienced by pts; c) in a solidarity health service (as the Italian one) the health decision-making is based on political and social basis, and not only on economic analysis; and d) usually the health decisions are based on a quantitative, and not qualitative, approach.
PIH24 PREFERENCES IN ITALIAN BPH PATIENTS

PIH25 THE COUPLE-PROJECT: POOLED ANALYSIS OF SATISFACTION WITH VARDENAFIL TREATMENT IN MEN WITH ERECTILE DYSFUNCTION AND THEIR PARTNERS
Evers T Bayer Healthcare AG, Wuppertal, Germany OBJECTIVES: To assess the influence of vardenafil on treatment satisfaction in men with erectile dysfunction (ED) and their female partners. METHODS: This was a retrospective pooled analysis of three multicentre, double-blind, flexible-dose, placebo-controlled clinical studies of vardenafil vs. placebo for 12 weeks, in men with ED for at least 6 months duration, and
